Eton Pharmaceuticals has initiated the ET-900 program to evaluate mecasermin, an IGF-1 based drug, for treating infantile and epileptic spasms, a severe form of epilepsy in children. The company licensed patent rights from Baylor College of Medicine and submitted an IND to the FDA for a Phase 2 trial starting in early 2027. This trial aims to test efficacy and safety in children with spasms resistant to current treatments, addressing a critical unmet medical need. Positive preclinical results showed significant reduction in spasms, supporting this new therapeutic approach.
Eton Pharmaceuticals' new ET-900 program for infantile and epileptic spasms is the subject here, with Pluang market data providing context. As of Nov 02, 2026 18:12 WIB, 70 of 150 priced Health-sector US stocks rose while 54 fell on Pluang. Notable movers include Twist Bioscience Corp (TWST) at USD 157.77 with a +3.27% change and a typical hold time of 27 days.
The global bio-based construction polymer market, valued at $18.2 billion in 2025, is projected to grow to $35 billion by 2033 at an 8.3% CAGR. Growth is fueled by rising demand for sustainable building materials that reduce greenhouse gas emissions ...
Annual Over-the-Air (OTA) software updates for software-defined vehicles (SDVs) are projected to reach over 2 billion globally by 2035, up from 546 million in 2025, driven by rising SDV sales and advanced vehicle software platforms. Level 3 and above...
Fram Wind Solutions AS, a joint venture partly owned by BW Offshore, secured a NOK 1.94 billion grant from Enova to develop a floating offshore wind project featuring two 18.5 MW turbines, the largest globally, with a combined capacity of 37 MW. The ...
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
